July 22, 2021
Article
The International Association for the Study of Lung Cancer (IASLC) has published an updated consensus on the use of liquid biopsy in screening non-small cell lung cancer (NSCLC).
July 21, 2021
The FDA has granted a breakthrough therapy designation for venetoclax following interim results from the ongoing M15-531 trial.
July 16, 2021
The FDA has approved belumosudil for the treatment of patients aged 12 years and older with chronic graft-versus-host disease following failure of at least 2 prior lines of therapy.
July 12, 2021
The FDA approval of daratumumab plus hyaluronidase-fihj (Darzalex Faspro) plus pomalidomide and dexamethasone (Pd) was supported by data from the APOLLO trial.
July 09, 2021
“For the first time, physicians can treat advanced urothelial cancer following treatment with a platinum-containing therapy and immunotherapy using an FDA-approved therapy that has demonstrated an OS benefit compared with chemotherapy.”
July 08, 2021
A trial evaluating melflufen in myeloma met its primary end point of progression free survival in the phase 3 OCEAN trial; however, overall survival was in favor of pomalidomide.
July 07, 2021
The FDA has offered support and encouragement for the development of paclitaxel plus encequidar.
July 01, 2021
The FDA has approved asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze) as a complement of treatment for the most common childhood cancer.
June 18, 2021
Many patients with cancer may feel uneasy about the COVID-19 vaccines, especially as new stories break about potential heart complications. However, most patients should get the shot as soon as possible, says Brahm Segal, MD.
June 15, 2021
Podcast
After hearing about the difficulties a transgender man faced in receiving a cancer diagnosis, Kelly S. Haviland, PhD, FNP-BC, found her calling.
